Eli Lilly & Co (LLY) DIvidends Date & History

Key Takeaways

• LLY offers a modest dividend yield of approximately 0.8%, reflecting its focus on growth over high current income.
• Quarterly dividend of $1.73 per share, with annual payout around $6.92, supported by strong earnings.
• 11-year streak of consecutive dividend increases, averaging 15% annual growth over the past 5 years.
• Payout ratio of about 26-27%, indicating high sustainability and room for future hikes.
• Robust earnings coverage from record 2025 profits, despite heavy capex pressures on free cash flow.
• Appeals to dividend growth investors seeking pharmaceutical sector exposure with total return potential.

Dividend Overview

Eli Lilly and Company (LLY), a leading pharmaceutical firm known for innovations like Mounjaro and Zepbound, maintains a quarterly dividend policy. The current quarterly dividend stands at $1.73 per share, declared on December 8, 2025, with an ex-dividend date of February 13, 2026, and payment on March 10, 2026. This equates to an annualized dividend of approximately $6.92, yielding around 0.8% at recent stock prices near $890-$920. LLY is classified as a dividend growth stock rather than a high-yield play, prioritizing reinvestment in R&D and manufacturing expansion while consistently raising payouts. The company's dividend profile emphasizes reliability and acceleration, with 15% year-over-year increases in recent years, appealing to investors focused on compounding income over time.

Dividend History and Growth

Eli Lilly has a long tradition of shareholder returns, paying dividends consistently for over 50 years. The company has raised its dividend for 11 consecutive years, with particularly strong growth in recent periods driven by blockbuster drug sales. Annual dividends have progressed from $4.52 in 2023 to $5.20 in 2024 and $6.00 in 2025, reflecting 15% increases each year. Quarterly payments have similarly advanced: from $1.13 in 2023, to $1.30 in 2024, $1.50 for most of 2025, and $1.73 starting Q1 2026. This trajectory underscores a long-term strategy of balancing growth investments with progressive payouts, without any cuts in modern history.

Dividend Sustainability and Payout Ratio

LLY's dividend sustainability is robust, bolstered by explosive earnings growth. The payout ratio hovers at 26-27% of earnings, well below levels that signal risk (typically over 60-75%). In 2025, Eli Lilly reported trailing twelve-month EPS of $22.95, providing ample coverage for the $6.92 annual dividend. Free cash flow (FCF) generation remains positive at approximately $6 billion TTM as of late 2025, though pressured by massive capital expenditures for manufacturing capacity amid GLP-1 demand surges—price-to-FCF exceeds 1,400 due to high stock valuation. Debt-to-equity stands at 160%, elevated from expansion financing, but manageable given $20+ billion in annual revenue and gross margins over 80%. Overall financial stability supports ongoing increases.

Dividend Compared to Industry Peers

Among large-cap pharmaceutical peers, LLY's ~0.8% yield is notably lower than the sector average of 2-3%. For instance, PFE offers over 6%, JNJ around 2.1%, MRK 2.8%, ABT 2.4%, AMGN 2.9%, and ABBV 3.2%. This reflects LLY's premium valuation as a growth leader in obesity and diabetes treatments, prioritizing capital appreciation and R&D over higher yields. Peers with mature portfolios provide more immediate income, while LLY trades at a growth discount on dividends.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover hidden gems in the pharmaceutical sector or beyond.

Is This Stock Attractive for Dividend Investors?

Eli Lilly (LLY) suits dividend growth investors who prioritize accelerating payouts and total returns over high current yields. Its 11-year increase streak and 15% CAGR appeal to those seeking compounding income alongside capital appreciation from innovative drugs like tirzepatide. Long-term holders may value the low payout ratio (26%), signaling capacity for sustained hikes amid projected revenue growth above 20%. However, conservative income seekers might prefer peers with 2-6% yields, as LLY's modest 0.8% offers limited immediate cash flow. The elevated debt-to-equity and capex-heavy FCF profile introduce mild risks, balanced by dominant market position. Growth-oriented dividend investors in healthcare could find alignment, while pure yield chasers may look elsewhere. Balanced portfolios blending growth and income might allocate modestly to LLY for diversification.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations